Skip to content
DataLookout
Menu

NCT07888621

Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System Lymphoma

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response Rate (ORR)
Timeframe: Assessed after Cycle 3 (Week 9) and after Cycle 6 (Week 18); each cycle is 21 days. Non-responders discontinue; responders are assessed through maintenance, up to approximately Week 36 (longer if ASCT or WBRT is interposed).

Secondary (4)

Complete Response Rate (CRR)
1-Year Progression-Free Survival (PFS) Rate
1-Year Overall Survival (OS) Rate
Incidence of Adverse Events and Serious Adverse Events

Arms and interventions

Glofitamab plus gemcitabine and oxaliplatin (GemOx)Experimental

Drugs: Glofitamab, Gemcitabine, Oxaliplatin, Obinutuzumab

Radiation: ASCT or whole-brain radiotherapy (WBRT)

Sites

1 site in 1 country

  • The First Affiliated Hospital with Nanjing Medical UniversityNanjing, Jiangsu, China